Daniel Arias
Stock Analyst at Stifel Nicolaus
(4.49)
# 1,058
Out of 5,128 analysts
538
Total ratings
50.7%
Success rate
9.4%
Average return
Main Sectors:
Stocks Rated by Daniel Arias
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MXCT MaxCyte | Reiterated: Buy | $4 | $1.19 | +236.13% | 18 | Nov 12, 2026 | |
| MASS 908 Devices | Reiterated: Buy | $12 → $14 | $9.79 | +43.00% | 18 | Nov 11, 2026 | |
| RGEN Repligen | Reiterated: Buy | $207 | $166.52 | +24.31% | 36 | Nov 11, 2026 | |
| MTD Mettler-Toledo International | Reiterated: Buy | $1,600 → $1,900 | $1,730.93 | +9.77% | 31 | Nov 10, 2026 | |
| GH Guardant Health | Reiterated: Buy | $180 | $154.86 | +16.23% | 19 | Nov 6, 2026 | |
| TXG 10x Genomics | Reiterated: Buy | $50 → $68 | $59.10 | +15.06% | 27 | Nov 6, 2026 | |
| BLLN BillionToOne | Reiterated: Buy | $145 | $110.79 | +30.88% | 5 | Nov 5, 2026 | |
| BRKR Bruker | Reiterated: Hold | $50 → $60 | $60.33 | -0.55% | 25 | Nov 5, 2026 | |
| MRVI Maravai LifeSciences Holdings | Reiterated: Buy | $8 → $9.5 | $7.68 | +23.70% | 26 | Nov 5, 2026 | |
| RVTY Revvity | Rated: Hold | $110 → $177 | $157.02 | +12.72% | 30 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $420 → $470 | $462.20 | +1.69% | 30 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $225 → $300 | $209.55 | +43.16% | 51 | Oct 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $15 → $18 | $15.62 | +15.24% | 20 | Oct 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $220 → $260 | $232.16 | +11.99% | 28 | Oct 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $775 | $699.44 | +10.80% | 35 | Oct 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $180 | $173.01 | +4.04% | 28 | Aug 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 → $32 | $31.76 | +0.76% | 3 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $40 | $50.10 | -20.16% | 21 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $0.671 | +1,092.25% | 7 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $60 → $50 | $75.89 | -34.12% | 12 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $65 → $50 | $72.84 | -31.36% | 28 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.9581 | n/a | 18 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $9.14 | n/a | 9 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $3.62 | n/a | 13 | Mar 1, 2024 |
MaxCyte
Nov 12, 2026
Reiterated: Buy
Price Target: $4
Current: $1.19
Upside: +236.13%
908 Devices
Nov 11, 2026
Reiterated: Buy
Price Target: $12 → $14
Current: $9.79
Upside: +43.00%
Repligen
Nov 11, 2026
Reiterated: Buy
Price Target: $207
Current: $166.52
Upside: +24.31%
Mettler-Toledo International
Nov 10, 2026
Reiterated: Buy
Price Target: $1,600 → $1,900
Current: $1,730.93
Upside: +9.77%
Guardant Health
Nov 6, 2026
Reiterated: Buy
Price Target: $180
Current: $154.86
Upside: +16.23%
10x Genomics
Nov 6, 2026
Reiterated: Buy
Price Target: $50 → $68
Current: $59.10
Upside: +15.06%
BillionToOne
Nov 5, 2026
Reiterated: Buy
Price Target: $145
Current: $110.79
Upside: +30.88%
Bruker
Nov 5, 2026
Reiterated: Hold
Price Target: $50 → $60
Current: $60.33
Upside: -0.55%
Maravai LifeSciences Holdings
Nov 5, 2026
Reiterated: Buy
Price Target: $8 → $9.5
Current: $7.68
Upside: +23.70%
Revvity
Nov 4, 2026
Rated: Hold
Price Target: $110 → $177
Current: $157.02
Upside: +12.72%
Nov 4, 2026
Rated: Hold
Price Target: $420 → $470
Current: $462.20
Upside: +1.69%
Oct 30, 2026
Reiterated: Buy
Price Target: $225 → $300
Current: $209.55
Upside: +43.16%
Oct 29, 2026
Reiterated: Hold
Price Target: $15 → $18
Current: $15.62
Upside: +15.24%
Oct 22, 2026
Reiterated: Buy
Price Target: $220 → $260
Current: $232.16
Upside: +11.99%
Oct 22, 2026
Reiterated: Buy
Price Target: $775
Current: $699.44
Upside: +10.80%
Aug 30, 2026
Reiterated: Buy
Price Target: $180
Current: $173.01
Upside: +4.04%
Aug 11, 2026
Reiterated: Buy
Price Target: $28 → $32
Current: $31.76
Upside: +0.76%
Aug 11, 2026
Reiterated: Hold
Price Target: $40
Current: $50.10
Upside: -20.16%
Aug 10, 2026
Reiterated: Buy
Price Target: $8
Current: $0.671
Upside: +1,092.25%
Aug 3, 2026
Reiterated: Hold
Price Target: $60 → $50
Current: $75.89
Upside: -34.12%
May 7, 2026
Reiterated: Hold
Price Target: $65 → $50
Current: $72.84
Upside: -31.36%
Nov 10, 2025
Reiterated: Buy
Price Target: $5
Current: $0.9581
Upside: n/a
Jan 22, 2025
Rated: Hold
Price Target: n/a
Current: $9.14
Upside: n/a
Mar 1, 2024
Reiterated: Buy
Price Target: $5
Current: $3.62
Upside: n/a